申请人:THE UNIVERSITY OF QUEENSLAND
公开号:US20200353048A1
公开(公告)日:2020-11-12
A method of treating a metabolic disorder of the liver includes administering a therapeutic agent. The therapeutic agent includes an IL-22 polypeptide and an antigen-binding molecule. The IL-22 polypeptide is fused or otherwise conjugated, directly or indirectly, to the antigen-binding molecule, and the antigen-binding molecule is an antibody or antigen-binding fragment that includes heavy and light chain CDR sequences.